UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

Leukemia, 2010-04, Vol.24 (4), p.699-705

2010

Volltextzugriff (PDF)

Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia

Leukemia research, 2012-10, Vol.36 (10), p.1283-1289

2012

Volltextzugriff (PDF)

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

Leukemia, 2011-12, Vol.25 (12), p.1808-1814

2011

Volltextzugriff (PDF)

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

Haematologica (Roma), 2015-09, Vol.100 (9), p.1172-1179

2015

Volltextzugriff (PDF)

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium

Leukemia, 2017-06, Vol.31 (6), p.1391-1397

2017

Volltextzugriff (PDF)

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia

Haematologica (Roma), 2016-08, Vol.101 (8), p.e320-e323

2016

Volltextzugriff (PDF)

Autotransplantation for relapsed or refractory Hodgkin's disease : long-term follow-up and analysis of prognostic factors

Bone marrow transplantation (Basingstoke), 1998-08, Vol.22 (3), p.265-271

1998

Volltextzugriff (PDF)

Phase I study for poor-prognosis lymphoma: Augmentation of the “BEAM” regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation — a preliminary report

Seminars in oncology, 2004-12, Vol.31 (6), p.59-61

2004

Volltextzugriff (PDF)

Treatment of deletion 5q acute myeloid leukemia with lenalidomide

Leukemia, 2007-03, Vol.21 (3), p.586-588

2007

Volltextzugriff (PDF)

Current status of clinical trials of farnesyltransferase inhibitors

Current opinion in oncology, 2001-11, Vol.13 (6), p.470-476

2001

Volltextzugriff (PDF)

Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia

Haematologica (Roma), 2013-01, Vol.98 (1), p.119-128

2013

Volltextzugriff (PDF)

Farnesyltransferase inhibitors (FTIs) in myeloid malignancies

Annals of hematology, 2004, Vol.83 Suppl 1, p.S87

2004

Volltextzugriff (PDF)

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

Haematologica (Roma), 2015-02, Vol.100 (2), p.231-237

2015

Volltextzugriff (PDF)

Acute myelogenous leukemia and aging. Clinical interactions

Hematology/oncology clinics of North America, 2000-02, Vol.14 (1), p.251

2000

Volltextzugriff (PDF)

CPX-351 versus cytarabine (CYT) and daunorubicin (DNR) therapy in newly diagnosed AML patients age 60-75: Safety and efficacy in secondary AML (sAML)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.6519-6519

2011

Volltextzugriff (PDF)

Between a Rux and a Hard Place: Investigating Causes of Ruxolitinib Discontinuation, Salvage Treatment and Outcome in Myelofibrosis

Blood, 2017, Vol.130, p.4186-4186

2017

Volltextzugriff (PDF)

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval

Clinical lymphoma, myeloma and leukemia, 2017-12, Vol.17 (12), p.e45-e53

2017

Volltextzugriff (PDF)

CPX-351 IN AML after failed induction with cytarabine and daunorubicin

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.6572-6572

2010

Volltextzugriff (PDF)

Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.6526-6526

2010

Volltextzugriff (PDF)

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia

BMC cancer, 2004-08, Vol.4 (1), p.56-56, Article 56

2004

Volltextzugriff (PDF)

Outcomes following induction chemotherapy in patients with AML arising from MDS: Analysis of prognostic factors

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.7088-7088

2009

Volltextzugriff (PDF)

Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory AML patients

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.7005-7005

2009

Volltextzugriff (PDF)

Erythroid response to lenalidomide (LEN) + recombinant erythropoietin (EPO) and endogenous serum EPO concentration in MDS cytokine-failures

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.7031-7031

2008

Volltextzugriff (PDF)

1 – 25 von 491

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(418)
Mit Volltextzugriff
(425)

Publikationsform

Sprache

Englisch
(483)
Spanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(82)
The Lancet
(38)
Journal Of Clinical Oncology
(24)
American Journal Of Human Genetics
(17)
Lancet
(16)
Genetics In Medicine
(13)
Leukemia Research
(12)
Biology Of Blood And Marrow Transplantation
(9)
Journal Of The National Comprehensive Cancer Network
(9)
Nature
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

Comparison of clinical outcomes and prognostic utility of risk stratification tools in patients with therapy-related vs de novo myelodysplastic syndromes: a report on behalf of the MDS Clinical Research Consortium

Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia

Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial

Autotransplantation for relapsed or refractory Hodgkin's disease : long-term follow-up and analysis of prognostic factors

Phase I study for poor-prognosis lymphoma: Augmentation of the “BEAM” regimen with escalating dose melphalan using amifostine cytoprotection and autologous hematopoietic stem cell transplantation — a preliminary report

Treatment of deletion 5q acute myeloid leukemia with lenalidomide

Current status of clinical trials of farnesyltransferase inhibitors

Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia

Farnesyltransferase inhibitors (FTIs) in myeloid malignancies

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

Acute myelogenous leukemia and aging. Clinical interactions

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

CPX-351 versus cytarabine (CYT) and daunorubicin (DNR) therapy in newly diagnosed AML patients age 60-75: Safety and efficacy in secondary AML (sAML)

Between a Rux and a Hard Place: Investigating Causes of Ruxolitinib Discontinuation, Salvage Treatment and Outcome in Myelofibrosis

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval

CPX-351 IN AML after failed induction with cytarabine and daunorubicin

Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia

Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia

Outcomes following induction chemotherapy in patients with AML arising from MDS: Analysis of prognostic factors

Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory AML patients

Erythroid response to lenalidomide (LEN) + recombinant erythropoietin (EPO) and endogenous serum EPO concentration in MDS cytokine-failures

Suchergebnisse filtern